Piacquad David 4
4 · AMGEN INC · Filed May 7, 2020
Insider Transaction Report
Form 4
AMGEN INCAMGN
Piacquad David
SVP, Business Development
Transactions
- Award
Common Stock
2020-05-05+1,269→ 42,773 total - Award
Nqso (Right to Buy)
2020-05-05+10,628→ 10,628 totalExercise: $236.36From: 2022-05-05Exp: 2030-05-05→ Common Stock (10,628 underlying)
Footnotes (4)
- [F1]The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.
- [F2]These shares include the following RSUs granted under the Company's equity plans: 335 RSUs which vest on 5/1/2021; 642 RSUs which vest in installments of 316 on 4/27/2021 and 326 on 4/27/2022; 1,691 RSUs which will vest in two installments of 558 on 5/3/2021 and 5/3/2022 and one installment of 575 on 5/3/2023; and 1,269 RSUs which vest in installments of 418 on 5/5/2022, 419 on 5/5/2023 and 432 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- [F3]These shares include 119 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.
- [F4]These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.